Roche (RHHBY) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124).
The study is...(read more
Pfizer Inc. (PFE) recently faced a pipeline setback with the company discontinuing a late-stage study being conducted with its oncology candidate, inotuzumab ozogamicin.
The randomized,...(read more
The following conversation took place between my wife and I a few months ago. Mrs. L: I really think you should get a flu shot this year. Me: I’ve never gotten one before and I’ve never come down with...(read more